Apramycin

This image is provided by the National Library of Medicine.

WikiDoc Resources for Apramycin
Articles
Most recent articles on Apramycin Most cited articles on Apramycin Review articles on Apramycin Articles on Apramycin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Apramycin Images of Apramycin Photos of Apramycin Podcasts & MP3s on Apramycin Videos on Apramycin
Evidence Based Medicine
Cochrane Collaboration on Apramycin Bandolier on Apramycin TRIP on Apramycin
Clinical Trials
Ongoing Trials on Apramycin at Clinical Trials.gov Trial results on Apramycin Clinical Trials on Apramycin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Apramycin NICE Guidance on Apramycin NHS PRODIGY Guidance FDA on Apramycin CDC on Apramycin
Books
Books on Apramycin
News
Apramycin in the news Be alerted to news on Apramycin News trends on Apramycin
Commentary
Blogs on Apramycin
Definitions
Definitions of Apramycin
Patient Resources / Community
Patient resources on Apramycin Discussion groups on Apramycin Patient Handouts on Apramycin Directions to Hospitals Treating Apramycin Risk calculators and risk factors for Apramycin
Healthcare Provider Resources
Symptoms of Apramycin Causes & Risk Factors for Apramycin Diagnostic studies for Apramycin Treatment of Apramycin
Continuing Medical Education (CME)
CME Programs on Apramycin
International
Apramycin en Espanol Apramycin en Francais
Business
Apramycin in the Marketplace Patents on Apramycin
Experimental / Informatics
List of terms related to Apramycin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Apramycin (also Nebramycin II) is an aminoglycoside antibiotic used in veterinary medicine. It is produced by Streptomyces tenebrarius.

Pharmacology

Indication

Apramycin is used for the treatment of bacterial infections in animals.

Mechanism of action

Apramycin stands out among aminoglycosides for its mechanism of action which is based on blocking translocation and its ability to bind also to the eukaryotic decoding site despite differences in key residues required for apramycin recognition by the bacterial target. The drug binds in the deep groove of the RNA which forms a continuously stacked helix comprising non-canonical C.A and G.A base pairs and a bulged-out adenine. The binding mode of apramycin at the human decoding-site RNA is distinct from aminoglycoside recognition of the bacterial target, suggesting a molecular basis for the actions of apramycin in eukaryotes and bacteria.

Spectrum of bacterial susceptibility and resistance

Apramycin can be used to treat bacterial infections in animals caused by Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The following shows susceptibility data on medically significant organisms:

• Escherichia coli - 1 μg/mL - >512 μg/mL (this large range may be due to resistant organisms, typical MIC values are likely in the range of 2 -8 μg/mL.
• Klebsiella pneumoniae - 2 μg/mL - >256 μg/mL
• Pseudomonas aeruginosa - 4 μg/mL